Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

Valneva (Group)

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees. *


Please contact us with your proposals. Thank you!
Period Start 2013-05-28 merged
  Predecessor Vivalis (Group)
Products Industry avian (bird) production technology (transgenic)
  Industry 2 vaccine
Persons Person Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
  Person 2 Grimaud, Franck (Vivalis 200702 CEO)
Region Region Lyon
  Country France
  Street 6 rue Alain Bombard
  City 44800 Saint-Herblain
    Address record changed: 2018-09-30
Basic data Employees D: 101 to 500 (2018-09-27)
  Currency EUR
  Annual sales 97,900,000 (revenues, total + grants (2016) 2016-12-31)
  Cash 42,200,000 (2016-12-31)
    * Document for �About Section�: Vivalis S.A.. (1/17/12). "Press Release: Vivalis and Sanofi Pasteur Extend Their 2010 Collaboration and License Contract with a New Human Monoclonal Antibody Discovery Target against a New Infectious Disease". Nantes, Lyon & Toyama.
Record changed: 2018-09-30


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Valneva (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top